Drug archive
Mibefradil (Systemic)
Archived drug information. This USP DI monograph is kept for reference and dates from the mid-2000s. Doses, warnings, interactions and brand names may have changed, and some products are no longer sold. Always follow your prescriber, your pharmacist and the current label, for example on DailyMed.
Category
- Antianginal
- antihypertensive
Description
Mibefradil (mi-be-FRA-dil) belongs to a group of medicines called calcium channel blocking agents, or, more commonly, calcium channel blockers.
Calcium channel blocking agents affect the movement of calcium into the cells of the heart and blood vessels. As a result, they relax blood vessels and increase the supply of blood and oxygen to the heart while reducing its workload.
Mibefradil is used to treat high blood pressure (hypertension). High blood pressure adds to the workload of the heart and arteries. If it continues for a long time, the heart and arteries may not function properly. This can damage the blood vessels of the brain, heart, and kidneys, resulting in a stroke, heart failure, or kidney failure. High blood pressure may also increase the risk of heart attacks. These problems may be less likely to occur if blood pressure is controlled.
Mibefradil is also used to treat recurring chest pain (angina pectoris). Angina occurs when the vessels that carry blood to the heart become narrowed and blocked, reducing the supply of blood and oxygen to the heart. As a result, chest tightness and/or a pressing or squeezing pain can occur. Mibefradil is thought to reduce angina by increasing the supply of blood and oxygen to the heart.
Mibefradil may also be used for other conditions as determined by your doctor.
The medicine was withdrawn from the U.S. market in May 1998.